Literature DB >> 19665319

A 10-year retrospective review of a nonrandomized cohort of 458 patients undergoing radical radiotherapy or cystectomy in Yorkshire, UK.

Nicholas P Munro1, Subramnian K Sundaram, Philip M T Weston, Lesley Fairley, Simon C W Harrison, David Forman, Rohit Chahal.   

Abstract

PURPOSE: We have previously reported on the mortality, morbidity, and 5-year survival of 458 patients who underwent radical radiotherapy or surgery for invasive bladder cancer in Yorkshire from 1993 to 1996. We aim to present the 10-year outcomes of these patients and to reassess factors predicting survival. METHODS AND MATERIALS: The Northern and Yorkshire Cancer Registry identified 458 patients whose cases were subjected to Kaplan-Meier all-cause survival analyses, and a retrospective casenote analysis was undertaken on 398 (87%) for univariate and multivariate Cox proportional hazards modeling. Additional proportional hazards regression modeling was used to assess the statistical significance of variables on overall survival.
RESULTS: The ratio of radiotherapy to cystectomy was 3:1. There was no significant difference in overall 10-year survival between those who underwent radiotherapy (22%) and radical cystectomy (24%). Univariate analyses suggested that female sex, performance status, hydronephrosis and clinical T stage, were associated with an inferior outcome at 10 years. Patient age, tumor grade, treatment delay, and caseload factors were not significant. Multivariate analysis models were created for 0-2 and 2-10 years after treatment. There were no significant differences in treatment for 0-2 years; however, after 2 years follow-up there was some evidence of increased survival for patients receiving surgery compared with radiotherapy (hazard ratio 0.66, 95% confidence interval: 0.44-1.01, p = 0.06).
CONCLUSIONS: a 10-year minimum follow-up has rarely been reported after radical treatment for invasive bladder cancer. At 10 years, there was no statistical difference in all-cause survival between surgery and radiotherapy treatment modalities.

Entities:  

Mesh:

Year:  2009        PMID: 19665319     DOI: 10.1016/j.ijrobp.2009.04.050

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  15 in total

1.  Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.

Authors:  Raymond H Mak; Daniel Hunt; William U Shipley; Jason A Efstathiou; William J Tester; Michael P Hagan; Donald S Kaufman; Niall M Heney; Anthony L Zietman
Journal:  J Clin Oncol       Date:  2014-11-03       Impact factor: 44.544

2.  Bladder preservation for localized muscle-invasive bladder cancer: the survival impact of local utilization rates of definitive radiotherapy.

Authors:  Kevin R Kozak; Maryam Hamidi; Matthew Manning; John S Moody
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-06       Impact factor: 7.038

Review 3.  Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.

Authors:  Skyler B Johnson; James B Yu
Journal:  Curr Oncol Rep       Date:  2018-06-30       Impact factor: 5.075

4.  Chemoradiation Vs Radical Cystectomy for Muscle-invasive Bladder Cancer: A Propensity Score-weighted Comparative Analysis Using the National Cancer Database.

Authors:  Dharam Kaushik; Hanzhang Wang; Joel Michalek; Michael A Liss; Qianqian Liu; Richa Priya Jha; Robert S Svatek; Ahmed M Mansour
Journal:  Urology       Date:  2019-08-08       Impact factor: 2.649

5.  SEOM clinical guidelines for the treatment of invasive bladder cancer.

Authors:  Rafael Morales; Albert Font; Joan Carles; Dolores Isla
Journal:  Clin Transl Oncol       Date:  2011-08       Impact factor: 3.405

6.  Use of radical cystectomy for patients with invasive bladder cancer.

Authors:  John L Gore; Mark S Litwin; Julie Lai; Elizabeth M Yano; Rodger Madison; Claude Setodji; John L Adams; Christopher S Saigal
Journal:  J Natl Cancer Inst       Date:  2010-04-16       Impact factor: 13.506

7.  Bladder preservation by concurrent chemoradiation for muscle-invasive bladder cancer: Applicability in low-income countries.

Authors:  Jamal Khader; Naim Farah; Ahmed Salem
Journal:  Rep Pract Oncol Radiother       Date:  2011-05-23

8.  Concurrent chemoradiotherapy improves survival outcome in muscle-invasive bladder cancer.

Authors:  Sang Jun Byun; Jin Hee Kim; Young Kee Oh; Byung Hoon Kim
Journal:  Radiat Oncol J       Date:  2015-12-30

9.  Clinical results of conformal versus intensity-modulated radiotherapy using a focal simultaneous boost for muscle-invasive bladder cancer in elderly or medically unfit patients.

Authors:  Lotte J Lutkenhaus; Rob M van Os; Arjan Bel; Maarten C C M Hulshof
Journal:  Radiat Oncol       Date:  2016-03-18       Impact factor: 3.481

Review 10.  Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers.

Authors:  Omar M S El-Taji; Sameer Alam; Syed A Hussain
Journal:  Curr Treat Options Oncol       Date:  2016-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.